Necrobiosis lipoidica therapy with biologicals: an ulcerated case responding to etanercept and a review of the literature
- PMID: 20805688
- DOI: 10.1159/000314694
Necrobiosis lipoidica therapy with biologicals: an ulcerated case responding to etanercept and a review of the literature
Abstract
Necrobiosis lipoidica (NL) is an idiopathic chronic granulomatous skin condition. There is currently no standardized effective treatment of NL. Ulceration occurs in up to 35% of cases. Treatment of ulcerative lesions is challenging and often unsuccessful. On the basis of the implication of the tumor necrosis factor alpha (TNF-alpha) on the formation of granulomas, since 2003 anti-TNF-alpha agents have been employed in cases of NL refractory to other therapeutic agents. We report a 50-year-old white woman with treatment-resistant chronic ulcerative NL of both shins successfully treated with subcutaneous etanercept. A review of the published literature suggests that biological agents (etanercept and infliximab) should be considered as a therapeutic alternative mainly in ulcerative NL unresponsive to prior conventional regimens. The dose and duration of treatment with these agents is not defined, therefore it is required to report management of these patients in order to develop an optimal therapeutic strategy.
Copyright 2010 S. Karger AG, Basel.
Similar articles
-
Anti-TNFα treatment for recalcitrant ulcerative necrobiosis lipoidica diabeticorum: A case report and review of the literature.Metabolism. 2016 Apr;65(4):569-73. doi: 10.1016/j.metabol.2015.12.014. Epub 2016 Jan 7. Metabolism. 2016. PMID: 26975548
-
Ulcerative necrobiosis lipoidica successfully treated with photodynamic therapy: case report and literature review.Photodiagnosis Photodyn Ther. 2014 Dec;11(4):516-8. doi: 10.1016/j.pdpdt.2014.08.002. Epub 2014 Aug 21. Photodiagnosis Photodyn Ther. 2014. PMID: 25150669 Review.
-
Perforating necrobiosis lipoidica in a girl with type 1 diabetes mellitus: a new case reported.Dermatol Online J. 2008 Jul 15;14(7):11. Dermatol Online J. 2008. PMID: 18718195 Review.
-
Treatment of necrobiosis lipoidica with the tumor necrosis factor antagonist etanercept.J Am Acad Dermatol. 2006 Mar;54(3 Suppl 2):S120-1. doi: 10.1016/j.jaad.2005.11.1042. J Am Acad Dermatol. 2006. PMID: 16488322 No abstract available.
-
Healing of severe ulcerative necrobiosis lipoidica with cyclosporin.Australas J Dermatol. 2004 May;45(2):119-22. doi: 10.1111/j.1440-0960.2004.00059.x. Australas J Dermatol. 2004. PMID: 15068460
Cited by
-
Shedding Light on Photodynamic Therapy in the Treatment of Necrobiosis Lipoidica: A Multicenter Real-Life Experience.Int J Mol Sci. 2024 Mar 23;25(7):3608. doi: 10.3390/ijms25073608. Int J Mol Sci. 2024. PMID: 38612420 Free PMC article.
-
The Intersection of Dermatological Dilemmas and Endocrinological Complexities: Understanding Necrobiosis Lipoidica-A Comprehensive Review.Biomedicines. 2024 Feb 1;12(2):337. doi: 10.3390/biomedicines12020337. Biomedicines. 2024. PMID: 38397939 Free PMC article. Review.
-
Molecularly Targeted Therapies for Inflammatory Cutaneous Granulomatous Disorders: A Review of the Evidence and Implications for Understanding Disease Pathogenesis.JID Innov. 2023 Aug 10;3(5):100220. doi: 10.1016/j.xjidi.2023.100220. eCollection 2023 Sep. JID Innov. 2023. PMID: 37719661 Free PMC article. Review.
-
Necrobiosis Lipoidica: Atypical Presentation in a Diabetic Girl.Case Rep Dermatol. 2021 Nov 30;13(3):547-552. doi: 10.1159/000520588. eCollection 2021 Sep-Dec. Case Rep Dermatol. 2021. PMID: 35082617 Free PMC article.
-
Use of fractionated microneedle radiofrequency for necrobiosis lipoidica.Lasers Med Sci. 2021 Aug;36(6):1337-1339. doi: 10.1007/s10103-020-03237-2. Epub 2021 Jan 3. Lasers Med Sci. 2021. PMID: 33389307 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
